GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Net Current Asset Value

SanBio Co (TSE:4592) Net Current Asset Value : 円39.49 (As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

SanBio Co's net current asset value per share for the quarter that ended in Jan. 2024 was 円39.49.

The historical rank and industry rank for SanBio Co's Net Current Asset Value or its related term are showing as below:

TSE:4592' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.47   Med: 12.46   Max: 248.61
Current: 11.52

During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of SanBio Co was 248.61. The lowest was 6.47. And the median was 12.46.

TSE:4592's Price-to-Net-Current-Asset-Value is ranked worse than
80.92% of 1027 companies
in the Biotechnology industry
Industry Median: 3.91 vs TSE:4592: 11.52

SanBio Co Net Current Asset Value Historical Data

The historical data trend for SanBio Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Net Current Asset Value Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.16 157.15 36.22 67.90 39.49

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.90 57.96 33.14 26.94 39.49

Competitive Comparison of SanBio Co's Net Current Asset Value

For the Biotechnology subindustry, SanBio Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where SanBio Co's Price-to-Net-Current-Asset-Value falls into.



SanBio Co Net Current Asset Value Calculation

SanBio Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jan. 2024 is calculated as

Net Current Asset Value Per Share(A: Jan. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4937.37-2254.893-0-0)/67.9289
=39.49

SanBio Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Jan. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jan. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4937.37-2254.893-0-0)/67.9289
=39.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co  (TSE:4592) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


SanBio Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of SanBio Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (TSE:4592) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines